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Abstract
The 2015 Varsity Medical Ethics debate convened upon the motion: “This house believes nootropic drugs should be
available under prescription”. This annual debate between students from the Universities of Oxford and Cambridge,
now in its seventh year, provided the starting point for arguments on the subject. The present article brings
together and extends many of the arguments put forward during the debate. We explore the current usage of
nootropic drugs, their safety and whether it would be beneficial to individuals and society as a whole for them to
be available under prescription. The Varsity Medical Debate was first held in 2008 with the aim of allowing students
to engage in discussion about ethics and policy within healthcare. The event is held annually and it is hoped that
this will allow future leaders to voice a perspective on the arguments behind topics that will feature heavily in
future healthcare and science policy. This year the Oxford University Medical Society at the Oxford Union hosted
the debate.
Abbreviations: (c), Captain; ADHD, Attention Deficit Hyperactivity Disorder; PET, Positron emission tomography;
RCT, Randomized controlled trial; UCL, University College, London
Background
The types methods of cognitive enhancement are multi-
farious in their mechanism and plausibility [1]. However,
compared to the abstract debate about enhancement in
general, pharmacological manipulation via existing pre-
scription drugs presents a very immediate ethical prob-
lem that requires attention.
The origin of the immediacy of this issue is twofold.
Firstly, the problem concerns drugs which are already le-
gally, safely and widely used amongst patient populations
[2]: Ritalin/Adderall for Attention Deficit Hyperactivity
Disorder (ADHD) and Modafinil for narcolepsy. Sec-
ondly, this method of enhancement is one that is actu-
ally in current use in an entirely unregulated fashion, by
a significant proportion of the population. In the U.K.
Ritalin and Adderall are considered class B drugs [3],
punishable up to 5 years in prison for possession, and
Modafinil is considered a prescription only medicine [4].
In the most recent large scale formal survey in The
United Kingdom & Ireland [5], the lifetime use of pre-
scription drugs that have purported cognitive enhancing
functions without a prescription in students has been es-
timated at around 10 %. Alarmingly, a further 20.4 %
have considered using such drugs, for which ‘lack of
availability’ was sighted as the major reason for not
using; suggesting the potential for a positive increase in
the future. The most common of these, Adderall, Me-
thylphenidate (Ritalin) and Modafinil are either obtained
from friends or online. Users obtain these drugs most
commonly with the aim of enhancing cognition (as op-
posed to offsetting sleep deprivation or enhancing
mood). Whilst estimates of the prevalence vary, results
from the United States (14 % of 381 respondents) [6]
and Switzerland (7.6 % of 6275 students), demonstrate
that non-prescription use of prescription only drugs for
the purposes of cognitive enhancement poses a signifi-
cant ethical problem.
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It should be noted that this article limits its scope to the
ethics of nootropic prescriptions on the NHS, rather than
economic arguments about allocating resources to such
drugs. We firstly discuss whether the use of these drugs
can be considered medically appropriate for cognitive en-
hancement. Secondly, we explore the ethical implications
of providing such drugs under prescription; analysing the
tension between providing a safe mechanism for their use,
and broader objections to ‘legitimising’ enhancement. We
argue a prescription framework provides the best frame-
work whilst also avoiding the ethical pitfalls that may arise
from making such drugs freely available.
Legitimate nootropic substances?
Before any claim can be made for the ethical benefits of
allowing such drugs to be provided by prescription for
nootropic purposes, we must satisfy the empirical ques-
tion as to whether these drugs should be considered as
nootropic. A meta-analysis [7] of 175 primary literature
studies of Modafinil in humans demonstrated significant
improvements in executive functions (most notably atten-
tion and memory) on both simple tasks and complex
tasks. However, only 24 studies employed a double blind
randomized control trial study design. Ritalin, in a meta
analysis of 19 randomized control trials [8], was found to
demonstrate a consistent effect specific to memory, but
failed to demonstrate an effect for other executive func-
tions. Repantis et al. also report an increase in attention
for Modafinil amongst non-sleep deprived subjects in a
meta-analysis of 31 RCT primary literature papers. Whilst
neither meta-analysis demonstrated no consistent serious
side effects, it should be noted that there is a potential for
abuse of amphetamine like substances (such as Ritalin/
Adderall) [9]. In sum, there is a small but growing body of
evidence to suggest that nootropic drugs can fulfil their
potential as cognitive enhancing agents, and therefore, we
argue that arguments that rest on dismissing their avail-
ability under prescription based efficacy are not sufficient.
Right to access
These days, no one would doubt that we live in a very fast-
paced society that is often highly pressurised. If this were
to cause symptoms in a patient as a consequence, such as
stress, a doctor or other professional would often advise
the individual to try and make their life less stressful.
However, we understand that the fast-paced nature of
society is unlikely to change and therefore finding
ways to cope is the best way forward. This leaves an
opening for nootropic drugs to help cope with the
demands of modern society.
Even if it is the case that certain nootropic substances
may help with such demands, the question arises as to
whether such substances should be available or whether
legalisation should ban its use. The right of access to
such drugs for a willing agent must be weighed against
the effect of granting that right to society as a whole.
Objections to the availability of cognitive enhancement
usually centre on the creation of an uneven playing field,
and the creation of a ‘burden to dope’ in the face of
culture that promotes enhancement [10].
Do nootropic drugs create an uneven playing field?
Whilst the use of cognitive enhancers clearly would pro-
vide some extra comparative benefit to a person, it does
so in the background of a plethora of inequalities (eco-
nomic, social, genetic, environmental) which can con-
tribute to inequalities in cognitive function. Secondly,
given that such substances are already being used (fairly
widely) for their nootropic effects, the playing field is
already tipped towards those who can afford them. By
providing them under legal prescription, we aim to re-
move economic and legal barriers to their access.
The creation of a ‘burden to dope’ provides a more ser-
ious challenge to the availability of nootropic drugs,
whether it be directly from another agent (such as an em-
ployer) or a more implicit burden to ‘keep up’ with other
agents who are using cognitive enhancing drugs. However,
to suggest that legal banning such substances would re-
move such a burden ignores the fact that this burden
already exists within certain populations; in an environment
of unregulated supply and lack of medical monitoring. Sec-
ondly, it naïvely assumes that by making such drugs avail-
able implies that they would be available unconditionally. If
the provision of such drugs would be held to the same stan-
dards as other healthcare services, i.e. that of patient auton-
omy (free from external constraints and having relevant
internal capacities to consent [11]), then it is unclear why
cognitive enhancement should be considered distinct from
other elective procedures such as plastic surgery. Therefore,
we argue that, carefully monitored, the right to access of
nootropic drugs should be advocated.
Need for prescriptions
The demand for nootropic drugs and the current state
of the law creates a situation whereby supply arises from
a black market. A key benefit of nootropic drugs becom-
ing available for prescription would be the licensing and
regulation processes that they would therefore be subject
to. For existing prescription drugs that are used without
a prescription, such as Ritalin and Modafinil, this means
that rather than purchasing from unregulated sources
such as friends or the internet, drugs would become
available from a legitimate source. This means someone
taking a nootropic knows exactly what they’re taking,
which is very difficult to qualify from an unregulated on-
line source, and what the potential side effects could be.
If a drug is prescribed from a physician the patient can be
monitored to observe for adverse side effects as well as ef-
ficacy. A system where a doctor has ‘control’ over a
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patient’s usage of a cognitive enhancing drug is inherently
safer than one where there is no experienced and profes-
sional input. The safety of individuals on the whole is of
critical importance and by this means efficacy can also be
monitored more efficiently on a widespread scale.
Creating a legal market for nootropics available under
prescription would also attract investment and research
into the field. Whilst we have highlighted the benefits of
certain drugs on cognitive functions, the field is marked
by a paucity of data on existing drugs in longitudinal stud-
ies. Particularly important here is the question of dosage
guidelines for nootropic consumption: PET scans illus-
trated that 400 mg of modafinil had observable effects in
parts of the brain involved in substance abuse and depend-
ence [12], and therefore clearly appropriate guidelines
need to be created for their consumption. However, such
research will only be forthcoming upon legitimising such a
use. Finally, it is worth noting that currently available noo-
tropics have arisen from drugs intended for use for par-
ticular diseases. Opening up the field would allow research
to begin on projects centred on pharmacological research
of cognitive enhancement, rather using existing molecules
for novel purposes (such as Ritalin or Modafinil).
Conclusion
An environment currently exists in society where the use
of nootropic drugs is widespread within certain groups of
people. We argue the reality of the situation should be ac-
cepted and everything done to make it as safe and regu-
lated as possible. By making these drugs available under
prescription, we argue that we will remove the negative ef-
fects of a ‘black market’ of prescription drugs whilst also
avoiding the potentials for abuse by making them freely
available. Furthermore, we argue that by incorporating
them into a formal medical framework, we will foster an
environment which promotes research and hopefully pro-
duces better nootropics for the future.
About the debate
After very persuasive arguments from both sides, the
judges awarded victory to the Cambridge team (propos-
ition) this year. A key area of contention was in the
safety of the nootropic drugs, with Oxford arguing that
regulation was undermined by the lack of solid data on
the effects of such drugs taken for solely nootropic bene-
fit. Cambridge argued, on the other hand, that the safety
and efficacy of consumption would be improved by their
availability under prescription from doctors, and that the
state had a duty to provide assistance to those who legit-
imately required the drugs for nootropic related reasons.
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